Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-08 am EDT			5-day change	1st Jan Change
7,397 ^JPY	-0.23%		+0.11%	+8.81%

Apr. 30	Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	CI
Apr. 25	Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI

Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021

February 31, 2021 at 11:00 pm EST

Shionogi & Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2021. For the period, the company expects Revenue of JPY 301,400 million, Operating profit of JPY 122,900 million, Profit attributable to owners of the parent of JPY 113,700 million or JPY 370.85 per basic share.

Latest news about Shionogi & Co., Ltd.

Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	Apr. 30	CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	Apr. 25	CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	Apr. 19	MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	Apr. 18	CI
Shionogi Completes Up to 75 Billion Yen Share Buyback	Mar. 29	MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	Mar. 28	CI
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	Mar. 21	CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	Mar. 20	CI
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	Mar. 07	MT
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	Mar. 06	MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval	Mar. 05	AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	Mar. 05	MT
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 05	CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	Mar. 04	RE
GSK's new HIV drug formula could support longer dosing intervals (March 4)	Mar. 04	RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	Mar. 04	RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings	Mar. 04	RE
FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd.	Mar. 03	CI
Jefferies Adjusts Shionogi’s Price Target to 7,600 Yen From 6,200 Yen, Keeps at Hold	Mar. 01	MT
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial	Feb. 27	AN
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan	Feb. 27	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	Feb. 26	MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	Feb. 26	DJ
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People	Feb. 21	MT

Chart Shionogi & Co., Ltd.

Duration

Period

More charts

Company Profile

Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Shionogi & Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7,414 JPY

Average target price

7,782 JPY

Spread / Average Target

+4.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHIONOGI & CO., LTD.	+8.81%	13.61B
ELI LILLY AND COMPANY	+33.43%	700B
NOVO NORDISK A/S	+27.95%	569B
JOHNSON & JOHNSON	-5.12%	358B
MERCK & CO., INC.	+19.59%	330B
ABBVIE INC.	+4.89%	287B
ASTRAZENECA PLC	+16.57%	236B
NOVARTIS AG	+6.74%	202B
ROCHE HOLDING AG	-9.16%	197B
AMGEN INC.	+4.26%	161B

Other Pharmaceuticals

Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Pharmaceuticals

Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021

EPS Revisions